RE: No revenue forcast24 Jan 2022 11:45
Glebe
Morning, not really an opinion more an observation.
Re Share Price generally
- A shareholders prime metric for the performance of the company (success/failure) maybe share price (naturally)
- A stakeholders prime metric for the performance of the company (success/failure) may not be share price but laboratory space, scientific breakthrough, receiving regulatory compliance, increase in staff etc etc
That said, DVRG are a 'Pharmaceutical Engineering' company and I believe that when GB comments on social media 'Significant news imminent' a shareholder interprets that as SP to rise while a stakeholder interprets that as scientific breakthrough/regulatory compliance etc
Also GB's narrative for a year is 'We are working hard to generate long term shareholder value and have no control over short term share price fluctuations' Again confirming my interpretation of DVRG's narrative.
In short, my observation is RNS'd 2022 revenue maybe useful to shareholders, even revitalise the share price but is not a requirement or desire for DVRG at this point. As you say triple digit growth is forecasted for 2022, that seems to suffice.
I have no opinion on if this stance is right or wrong btw
Not aimed at you, just a general observation
ATBG